European Archives of Oto-Rhino-Laryngology

, Volume 275, Issue 2, pp 325–333 | Cite as

Safety of intranasal corticosteroid sprays during pregnancy: an updated review

  • Ahmed H. Alhussien
  • Riyadh A. Alhedaithy
  • Saad A. Alsaleh
Review Article

Abstract

Introduction

Rhinitis and rhinosinusitis are commonly encountered in pregnant women. Intranasal corticosteroid (INCS) sprays are generally safe and effective in the treatment of these conditions in the general population. However, the use of some of these INCS sprays during pregnancy is still controversial.

Objective

To review the current literature about the safety of intranasal corticosteroid sprays during pregnancy.

Methodology

Using different search engines, each type of INCS was reviewed separately (triamcinolone, beclomethasone, budesonide, fluticasone propionate, fluticasone furoate, mometasone, and ciclesonide). A total of 51 full-length articles were examined for eligibility. After applying inclusion and exclusion criteria, a total of three articles were reviewed.

Results

No significant association with congenital organ malformations has been linked to intranasal use of beclomethasone, budesonide, fluticasone propionate, fluticasone furoate, or mometasone. Intranasal triamcinolone, however, has been found to have a significant association with respiratory tract defects. Data about the safety of intranasal ciclesonide during pregnancy are not available.

Conclusion

Lacking sufficient clinical trials on the use of intranasal corticosteroid sprays in pregnancy, we suggest that the intranasal use of fluticasone furoate, mometasone, and budesonide is safe if they are used at the recommended therapeutic dose after a proper medical evaluation. Intranasal fluticasone propionate might be a safe option in the absence of other INCS options due to its questionable efficacy during pregnancy. Risk-benefit ratio should always be considered before prescribing any intranasal corticosteroid sprays during pregnancy.

Keywords

Intranasal Corticosteroids Safety Pregnancy Rhinitis Sinusitis 

Notes

Compliance with ethical standards

Funding

No funding was received for this study.

Conflict of interest

Authors have no conflict of interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Bende M, Gredmark T (1999) Nasal stuffiness during pregnancy. Laryngoscope 109:1108–1110. doi: 10.1097/00005537-199907000-00018 CrossRefPubMedGoogle Scholar
  2. 2.
    Hamano N (1998) Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 19:263–269CrossRefPubMedGoogle Scholar
  3. 3.
    Schatz M, Zeiger RS (1988). Diagnosis and management of rhinitis during pregnancy. Allergy Asthma Proc 9(5):545–554CrossRefGoogle Scholar
  4. 4.
    Wei W, Liu H, Kang D et al (2015) Non-surgical interventions for nasal congestion during pregnancy. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD011653 PubMedCentralGoogle Scholar
  5. 5.
    Yawn B, Knudtson M (2007) Treating asthma and comorbid allergic rhinitis in pregnancy. J Am Board Fam Med 20:289–298. doi: 10.3122/jabfm.2007.03.060144 CrossRefPubMedGoogle Scholar
  6. 6.
    Ellegård EK (2006) Pregnancy rhinitis. Immunol Allergy Clin North Am 26:119–135. doi: 10.1016/j.iac.2005.10.007 CrossRefPubMedGoogle Scholar
  7. 7.
    Incaudo GA (2004) Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation. Clin Rev Allergy Immunol 27:159–177. doi: 10.1385/criai:27:2:159 CrossRefPubMedGoogle Scholar
  8. 8.
    Gilbey P, McGruthers L, Morency A-M, Shrim A (2012) Rhinosinusitis-related quality of life during pregnancy. Am J Rhinol Allergy 26:283–286. doi: 10.2500/ajra.2012.26.3776 CrossRefPubMedGoogle Scholar
  9. 9.
    Caparroz FA, Gregorio LL, Bongiovanni G et al (2016) Rhinitis and pregnancy: literature review. Braz J Otorhinolaryngol 82:105–111. doi: 10.1016/j.bjorl.2015.04.011 CrossRefPubMedGoogle Scholar
  10. 10.
    Pien GW, Schwab RJ (2004) Sleep disorders during pregnancy. Sleep 27:1405–1417CrossRefPubMedGoogle Scholar
  11. 11.
    Kaiser HB, Liao Y, Diener P et al (2004) Triamcinolone acetonide and fluticasone propionate nasal sprays provide comparable relief of seasonal allergic rhinitis symptoms regardless of disease severity. Allergy Asthma Proc 25:423–428PubMedGoogle Scholar
  12. 12.
    Mak KK, Ku MS, Lu KH et al (2013) Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol 54:239–245. doi: 10.1016/j.pedneo.2013.01.007 CrossRefPubMedGoogle Scholar
  13. 13.
    Newson-Smith G, Powell M, Baehre M et al (1997) A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 254:236–241CrossRefPubMedGoogle Scholar
  14. 14.
    Trangsrud AJ, Whitaker AL, Small RE (2002) Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 22:1458–1467. doi: 10.1592/phco.22.16.1458.33692 CrossRefPubMedGoogle Scholar
  15. 15.
    Weiner JM, Abramson MJ, Puy RM (1998) Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 317:1624–1629. doi: 10.1136/bmj.317.7173.1624 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sheikh A, Panesar SS, Salvilla S (2009) Ear, nose, and throat disorders Hay fever in adolescents and adults Ear, nose, and throat disorders Hay fever in adolescents and adults. BMJ clinical evidenceGoogle Scholar
  17. 17.
    Day J, Carrillo T (1998) Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol 102:902–908CrossRefPubMedGoogle Scholar
  18. 18.
    Fokkens W, Lund V, Mullol J (2012) European position paper on rhinosinusitis and nasal polyps. Rhinology 1–136. doi: 10.4193/Rhino50E2
  19. 19.
    Allen DB (2000) Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 106:S179-90. doi: 10.1067/mai.2000.110038 CrossRefPubMedGoogle Scholar
  20. 20.
    Corren J (1999) Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 104:S144-9. doi: 10.1016/S0091-6749(99)70310-6 CrossRefPubMedGoogle Scholar
  21. 21.
    Boner AL (2001) Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. J Allergy Clin Immunol 108:32–39. doi: 10.1067/mai.2001.115564 CrossRefGoogle Scholar
  22. 22.
    Kim KT, Rabinovitch N, Uryniak T et al (2004) Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 93:61–67. doi: 10.1016/S1081-1206(10)61448-2 CrossRefPubMedGoogle Scholar
  23. 23.
    Wilson a M, McFarlane LC, Lipworth BJ (1998) Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 101:470–474. doi: 10.1016/S0091-6749(98)70354-9 CrossRefPubMedGoogle Scholar
  24. 24.
    Sastre J, Mosges R (2012) Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 22:1–12PubMedGoogle Scholar
  25. 25.
    Wihl J-Å, Andersson K-E, Johansson S-Å (1997) Systemic effects of two nasally administered glucocorticosteroids. Allergy 52:620–626. doi: 10.1111/j.1398-9995.1997.tb01040.x CrossRefPubMedGoogle Scholar
  26. 26.
    Ramoz LL, Patel-Shori NM (2014) Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy 34:389–395. doi: 10.1002/phar.1385 CrossRefPubMedGoogle Scholar
  27. 27.
    Broek JL, Bousquet J, Baena-Cagnani CE et al (2010) Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 126:466–476. doi: 10.1016/j.jaci.2010.06.047 CrossRefGoogle Scholar
  28. 28.
    Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions : explanation and elaboration. doi: 10.1371/journal.pmed.1000100
  29. 29.
    Bérard A, Sheehy O, Kurzinger M-L, Juhaeri J (2016) Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. J Allergy Clin Immunol 138:97–104.e7. doi: 10.1016/j.jaci.2016.01.021 CrossRefPubMedGoogle Scholar
  30. 30.
    Källén BAJ, Otterblad Olausson P (2003) Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17:255–261. doi: 10.1016/S0890-6238(03)00012-1 CrossRefPubMedGoogle Scholar
  31. 31.
    Ellegård EK, Hellgren M, Karlsson NG (2001) Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol Allied Sci 26:394–400. doi: 10.1046/j.1365-2273.2001.00491.x CrossRefPubMedGoogle Scholar
  32. 32.
    Pelucchi Foresi a, Gherson A G, et al (1996) Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 98:274–282CrossRefPubMedGoogle Scholar
  33. 33.
    Daley-Yates PT, Price AC, Sisson JR et al (2001) Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51:400–409. doi: 10.1046/j.0306-5251.2001.01374.x CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Dawes M, Chowienczyk PJ (2001) Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 15:819–826. doi: 10.1053/beog.2001.0231 CrossRefPubMedGoogle Scholar
  35. 35.
    Kallen B, Rydhstroem H, Aberg A (1999) Congenital malformations after the use of inhaled budesonide in early pregnancy. Am J Obstet Gynecol 93:392–395Google Scholar
  36. 36.
    Norjavaara E, De Verdier MG (2003) Normal pregnancy outcomes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 111:736–742. doi: 10.1067/mai.2003.1340 CrossRefPubMedGoogle Scholar
  37. 37.
    Renu Lal Pharm.D (2015) Drugs in pregnancy and lactation: improved benefit-risk information. Food and Drug Administration (FDA) https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM431132.pdf. Accessed 24 Jan 2017
  38. 38.
    Noordzij M, Dekker FW, Zoccali C, Jager KJ (2009) Study designs in clinical research. Nephron Clin Pract. doi: 10.1159/000235610 PubMedGoogle Scholar
  39. 39.
    Carlson MDA, Ph D, Morrison RS (2009) A user’ s guide to research in palliative care study design, precision, and validity in observational studies. J Palliat Med 12(1):77–82. doi: 10.1089/jpm.2008.9690 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Daley-Yates PT, Kunka RL, Yin Y et al (2004) Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 60:265–268. doi: 10.1007/s00228-004-0763-y CrossRefPubMedGoogle Scholar
  41. 41.
    Daley-yates PT, Price AC, Sisson JR et al (2001) Beclomethasone dipropionate : absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51(5):400–409CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Thorsson L, Borga O, Edsbacker S (1999) Systemic availability of budesonide after nasal administration of three different formulations; pressurized aerosol, aqueous spray pump and powder. Br J Clin Pharmacol 47:619–624. doi: 10.1046/j.1365-2125.1999.00956.xf CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Allen A, Down G, Newland A et al (2007) Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 29:1415–1420. doi: 10.1016/j.clinthera.2007.07.028 CrossRefPubMedGoogle Scholar
  44. 44.
    Nave R, Herzog R, Laurent A, Wingertzahn MA (2009) Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy vol. Clin Ther 31:2988–2999. doi: 10.1016/j.clinthera.2009.12.002 CrossRefPubMedGoogle Scholar
  45. 45.
    Shekelle PG, Woolf SH, Eccles M, Grimshaw J (1999) Developing clinical guidelines. West J Med 170:348–351PubMedPubMedCentralGoogle Scholar
  46. 46.
    Lal D, Jategaonkar AA, Borish L et al (2016) Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations. Rhinology 54:99–104. doi: 10.4193/Rhino15.228 PubMedGoogle Scholar
  47. 47.
    Wallace DV, Dykewicz MS, Bernstein DI et al (2008) The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 122:1–84. doi: 10.1016/j.jaci.2008.06.003 CrossRefGoogle Scholar
  48. 48.
    Walker SM, Durham SR, Till SJ et al (2011) Immunotherapy for allergic rhinitis. Clin Exp Allergy 41:1177–1200. doi: 10.1111/j.1365-2222.2011.03794.x CrossRefPubMedGoogle Scholar
  49. 49.
    Seidman MD, Gurgel RK, Lin SY et al (2015) Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg 152:S1–S43. doi: 10.1177/0194599814561600 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Ahmed H. Alhussien
    • 1
  • Riyadh A. Alhedaithy
    • 2
  • Saad A. Alsaleh
    • 3
  1. 1.College of MedicineKing Saud UniversityRiyadhSaudi Arabia
  2. 2.Division of Otolaryngology, Head and Neck Surgery, Department of SurgeryKing Abdulaziz Medical City, National Guard Health AffairsRiyadhSaudi Arabia
  3. 3.Rhinology and Endoscopic Skull Base Surgery Unit, Otolaryngology, Head and Neck Surgery DepartmentKing Saud University Medical CityRiyadhSaudi Arabia

Personalised recommendations